Companies › Napo Pharmaceuticals
1 active drug program in 1 registered trial: 1 Phase 2; Other; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Crofelemer Cystic fibrosis transmembrane conductance regulator inhibitor; Anoctamin-1 blocker | CFTR, ANO1 | Phase 2 | Microvillus Inclusion Disease | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06721871 | Crofelemer | Phase 2 | Microvillus Inclusion Disease | Other | Dec 2026 |
Vertex Pharmaceuticals Napo Therapeutics 4D Molecular Therapeutics ReCode Therapeutics Qanatpharma Krystal Biotech Boehringer Ingelheim Arcturus Therapeutics
Healx Skingenix Sensory Cloud Shanghai Huilun Pharmaceutical Dendrogenix
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.